^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    golidocitinib (DZD4205)

    i
    Other names: DZD4205, AZD-4205, AZD 4205, AZD4205, DZD-4205
    Company:
    Dizal Pharma
    Drug class:
    JAK1 inhibitor
    Related drugs:
    5d
    Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) (clinicaltrials.gov)
    P1/2, N=165, Recruiting, Dizal Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    doxorubicin hydrochloride • cyclophosphamide • golidocitinib (DZD4205)
    9d
    Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Beijing Tongren Hospital
    New P1/2 trial
    |
    etoposide IV • dexamethasone • Oncaspar liquid (pegaspargase) • golidocitinib (DZD4205) • Duoenda (mitoxantrone liposomal)
    22d
    T-START-M1: Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma (clinicaltrials.gov)
    P3, N=136, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    golidocitinib (DZD4205)
    25d
    Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) (clinicaltrials.gov)
    P1/2, N=165, Not yet recruiting, Dizal Pharmaceuticals
    New P1/2 trial
    |
    doxorubicin hydrochloride • cyclophosphamide • golidocitinib (DZD4205)
    28d
    Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL (clinicaltrials.gov)
    P1/2, N=86, Not yet recruiting, Ruijin Hospital
    New P1/2 trial
    |
    azacitidine • decitabine • Epidaza (chidamide) • zeprumetostat (SHR-2554) • golidocitinib (DZD4205)
    1m
    PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL (clinicaltrials.gov)
    P2, N=47, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epidaza (chidamide) • golidocitinib (DZD4205)
    1m
    Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26). (PubMed, Blood Cancer J)
    No TRAEs leading to fatal outcomes were reported. This study suggests the potential of golidocitinib as maintenance therapy for patients with PTCL.
    P2 data • Journal
    |
    JAK1 (Janus Kinase 1)
    |
    golidocitinib (DZD4205)
    2ms
    JACKPOT38: Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC (clinicaltrials.gov)
    P2, N=20, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    golidocitinib (DZD4205)
    2ms
    Case Report: Targeting the Achilles' heel of monomorphic epitheliotropic intestinal T-cell lymphoma. (PubMed, Front Oncol)
    We report the case of a 34-year-old female with refractory MEITL who failed prior lines of therapy, including CHOPE and gemcitabine/oxaliplatin (GemOx) combined with golidocitinib. Future efforts should focus on optimizing combination partners for venetoclax to improve efficacy and tolerability. The rationale for exploring venetoclax as post-transplant maintenance therapy in MEITL is also discussed.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • gemcitabine • oxaliplatin • golidocitinib (DZD4205)
    2ms
    T-START-M1: Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial (clinicaltrials.gov)
    P3, N=68, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New P3 trial
    |
    ALK negative
    |
    golidocitinib (DZD4205)
    3ms
    PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    Epidaza (chidamide) • golidocitinib (DZD4205)
    3ms
    Golidocitinib Combined With Selinexor for CAEBVD (clinicaltrials.gov)
    P2/3, N=28, Recruiting, Beijing Friendship Hospital
    New P2/3 trial
    |
    Xpovio (selinexor) • golidocitinib (DZD4205)